(MedPage Today) — SAN FRANCISCO — Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease control with a novel KRAS G12D inhibitor, a small preliminary study showed.
The early results showed that…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
